Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Lenalidomide 11Dexamethasone 11fludarabine 9Cyclophosphamide 7Bortezomib 6fludarabine phosphate 5Melphalan 5pomalidomide 4isatuximab 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Busulfan 3dacetuzumab 2Whole-Body Irradiation 2Thiotepa 2Stem Cell Transplantation 2Leukapheresis 2KW-2478 2Granulocyte Colony-Stimulating Factor 2Cyclosporine 2Calcium Dobesilate 2tanespimycin 1spartalizumab 1sargramostim 1ricolinostat 1pirtobrutinib 1pembrolizumab 1nirogacestat 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Bismuth × Plasma cell × Clear all
NCT00892502 2013-09-10

Bismuth-PBH

Copenhagen University Hospital at Herlev

Phase NA Completed
50 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡